Jin Rong Jie·2025-07-14 08:28Group 1 - The core viewpoint of the articles highlights the performance of the CSI 300 Pharmaceutical Index, which closed at 11,931.35 points, showing a decline of 1.18% over the past month, an increase of 7.25% over the past three months, and a year-to-date increase of 9.53% [1][2] - The CSI 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the CSI 300 Index, reflecting the overall performance of these companies [1] - The top ten weighted companies in the CSI 300 Pharmaceutical Index include: Heng Rui Medicine (43.14%), Pian Zai Huang (10.14%), Yunnan Baiyao (8.49%), Kelun Pharmaceutical (6.31%), East China Pharmaceutical (5.98%), New Harmony (5.69%), Fosun Pharmaceutical (5.53%), Tong Ren Tang (4.16%), Bai Li Tian Heng (3.83%), and China Resources Sanjiu (3.54%) [1] Group 2 - The market share of the CSI 300 Pharmaceutical Index is dominated by the Shanghai Stock Exchange at 69.99%, while the Shenzhen Stock Exchange accounts for 30.01% [2] - In terms of industry composition, the index is primarily made up of drug formulations at 64.78%, traditional Chinese medicine at 29.52%, and raw materials at 5.69% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year, and weights are fixed until the next scheduled adjustment [2]